Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis

Multiple Sclerosis

Volumn 11, Issue 6, 2005, Pages 658-668

  Gupta, S ^a,b   Solomon, J M ^c   Tasciyan, T A ^c   Cao, M M ^a   Stone, R D ^a   Ostuni, J L ^a   Ohayon, J M ^a   Muraro, P A ^a   Frank, J A ^d   Richert, N D ^a   McFarland, H F ^a   Bagnato, Francesca ^a,e  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c Medical Numerics Inc   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NONE   (United States)

Author keywords

Contrast enhancing lesions; Interferon beta; Lesion sizes; Magnetic resonance imaging; Multiple sclerosis; Re enhancing lesions

Indexed keywords

INTERFERON BETA SERINE;

ADULT; ARTICLE; BRAIN INJURY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HUMAN; IMAGE ANALYSIS; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; FEMALE; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 28044453525     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1229oa     Document Type: Article

References (34)

1. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-27.
2. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32: 758-66.
3. Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993; 116: 1077-94.
4. Bastianello S, Pozzilli C, Bernardi S, Bozzao L, Fantozzi LM, Buttinelli C et al. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology 1990; 40: 591-95.
5. Hawkins CP, Munro PM, MacKenzie F, Kesselring J, Tofts PS, du Boulay EP et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990; 113: 365-78.
6. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990; 113: 1477-89.
7. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29: 548-55.
8. Stone LA, Frank JA, Albert PS, Bash CN, Smith ME, Maloni H et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37: 611-19.
9. McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 2002; 8: 40-51.
10. Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, Millefiorini E et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short-term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 61: 251-58.
11. Filippi M, Rovaris M, Capra R, Gasperini C, Prandini F, Martinelli V et al. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. J Neurol Neurosurg Psychiatry 1999; 67: 386-89.
12. Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European study group on interferon-beta1b in secondary progressive multiple sclerosis. Ann Neurol 1999; 46: 850-59.
13. Brex PA, Molyneux PD, Smiddy P, Barkhof F, Filippi M, Yousry TA et al. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001; 57: 2185-90.
14. Barkhof F, Scheltens P, Frequin ST, Nauta JJ, Tas MW, Valk J et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol 1992; 159: 1041-47.
15. van Waesberghe JH, van Walderveen MA, Castelijns JA, Scheltens P, Lycklama a Nijeholt GJ et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998; 19: 675-83.
16. Ciccarelli O, Giugni E, Paolillo A, Mainero C, Gasperini C, Bastianello S et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 1999; 6: 455-59.
17. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into 'black holes'. Neurology 2001; 57: 731-33.
18. Columba-Cabezas S, Serafini B, Ambrosini E, Aloisi F. Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation. Brain Pathol 2003; 13: 38-51.
19. Lehmann PV, Sercarz EE, Forsthuber TG, Dayan CM, Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 1993; 14: 203-208.
20. Brenchley JM, Douek DC, Ambrozak DR, Chatterji M, Betts MR, Davis LS et al. Expansion of activated human naïve T-cells precedes effector function. Clin Exp Immunol 2002; 130: 432-40.
21. Targoni OS, Baus J, Hofstetter HH, Hesse MD, Karulin AY, Boehm BO et al. Frequencies of neuroantigen-specific T cells in the central nervous system versus the immune periphery during the course of experimental allergic encephalomyelitis. J Immunol 2001: 166: 4757-64.
22. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
23. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
24. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002; 59: 1496-506.
25. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44-51.
26. Medical Numerics, Inc. MEDx 3.42. Retrieved October 2004 from www.medicalnumerics.com
27. Jenkinson M, Smith S. A global optimisation method for robust affine registration of brain images. Med Image Anal 2001; 5: 143-56.
28. Cohen MS, DuBois RM, Zeineh MM. Rapid and effective correction of RF inhomogeneity for high field magnetic resonance imaging. Hum Brain Mapp 2000; 10: 204-11.
29. Russ JC. The image processing handbook, first edition. Boca Raton: CRC Press, 1992.
30. Rosner B. Fundamentals of biostatistics, fifth edition. Australia: Duxbury, 2000.
31. Cotton F, Weiner HL, Jolesz FA, Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003; 60: 640-46.
32. Hiehle JF, Grossman RI, Ramer KN, Gonzalez-Scarano F, Cohen JA. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol 1995; 16: 69-77.
33. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-93.
34. Paolillo A, Bastianello S, Frontoni M, Gasperini C, Giugni E, Ciccarelli O et al. Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. J Neurol 1999; 246: 443-48.